Navigation Links
Should Genetic Information Be Disclosed to Insurers?

There is no good reason to deny insurers access to genetic information, argues a Professor of Ethics in a debate published in this weeks BMJ.

Only if we refuse to give insurers access to all health information can we reasonably stop them seeking genetic test results, says Professor Soren Holm from Cardiff Law School.

If insurers were denied access to any health information they would only be able to differentiate premiums according to very general risk markers, for example, age, gender or occupation. This would mean in effect that the healthy subsidise the unhealthy but there would be equality.

However, if we allow insurers to have some kinds of health information, such as a persons BMI or cholesterol level we no longer have any principled reason for excluding genetic information:

Genetic information is not special. It is not inherently more specific, predictive, sensitive or private than other kinds of health information.

Professor Holm concedes there are worries about sharing genetic information - allowing insurers to see genetic information could deter people from getting tested or insurers may use the information inappropriately. This may be the case, he says, but the same is true for other health information for example whether someone is HIV positive.

He argues a better solution to this problem would be to make challengeable a decision to deny coverage for life or health insurance, thereby forcing insurers to make their reasoning transparent.

On the other side of the argument Professor Richard Ashcroft from the University of London says access to genetic information should not be allowed as it could lead to irrational discrimination. This arises, he says, from false beliefs about genetic information. It can be misunderstood or its significance over-estimated.

He says if insurers had access to complete health information, including genetic test res ults, it could lead to a situation which was actuarially fair but socially unfair:

If the point of insurance is to cover the costs of ill luck, the only sort of ill luck you could not insure against would be the misfortune to have a late onset serious genetic disorder. Arguably such people would need insurance more than most yet would be less able than most to get it.

In the face of uncertainty surrounding the interpretation of genetic information, occasional discriminatory practice by individual insurers and a lack of solutions to the problem of social justice, he says, it is preferable to maintain the status quo, at least in the medium term.


'"/>




Related medicine news :

1. Babies Should Get Vitamin D Supplement
2. How Much Should Athletes Drink?
3. Angioplasty Should be the Standard
4. Parents Should Look For Signs Of Children Becoming Overweight
5. Diabetics Should Adopt Better Preventive Measures
6. Before Weight Loss Surgery One Should Get Tested for Bacteria
7. Should we avoid energy drinks to protect our teeth?
8. Parents Should Beware of Violent Video Games
9. Exercises Should Be Recommended During Pregnancy
10. Khushboo Should ‘Talk about Safe Sex’ and not ‘ Premarital Sex’ Says Miniter
11. Government Should Restrict Junk Food Marketing
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/26/2017)... ... April 26, 2017 , ... New ... of ready-to-drink, high-protein beverages by helping beverage manufacturers more effectively manage protein costs. ... direct cost savings as well as more stable pricing over time. Now it’s ...
(Date:4/26/2017)... ... April 26, 2017 , ... MYOLYN, a medical ... that it has received 510(k) clearance from the U.S. Food & Drug Administration ... Pro. , Both devices are stationary cycling systems that use MYOLYN’s patent-pending ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... collaboration, announces Mirroring360 Pro . This new addition to the Mirroring360 product ... for education and business. , Mirroring360 Pro enables educators, business professionals and individuals ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... Beach, California, committed to raising awareness for Duchenne muscular dystrophy, and funding ... randomized CAP-1002 (cardiosphere-derived cells) Phase I/II HOPE clinical trial in Duchenne announced ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... CFOs and HR decision-makers are preparing for how his administration could impact the ... provide insight into what changes are most likely to make it through Congress. ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... April 19, 2017 The Mobile X-Ray product segment ... healthy CAGR during the forecast period Mobile X-Ray ... global digital mobile X-Ray devices market, which is estimated to ... expanding at a CAGR of 7% over the forecast period. ... of more than US$ 100 Mn in 2017 over 2016. ...
(Date:4/19/2017)... Global Prostate Cancer Therapeutics Market: Overview ... cancer therapeutics market analyzes the current and future ... prostate cancer, launch of promising emerging therapies, as ... drugs & therapeutic biological products, and high growth ... side effects are some of the drivers expected ...
(Date:4/19/2017)...  Sorrento Therapeutics, Inc. (NASDAQ: SRNE ... new treatments for cancer and other unmet medical ... announced underwritten public offering of 23,625,084 shares of ... of $2.00 per share, before deducting underwriting discounts ... Sorrento.  The net proceeds to Sorrento from this ...
Breaking Medicine Technology: